AstraZeneca plc (AZN)
Stock Price Chart
Key Info
| Market Cap | 138.08B |
| Revenue (ttm) | 25.87B |
| Net Income (ttm) | 2.42B |
| Shares Out | 2.62B |
| EPS (ttm) | 0.95 |
| PE Ratio | 55.38 |
| Forward PE | 22.83 |
| Dividend | $1.40 |
| Dividend Yield | 2.66% |
Stock Quote
| Trading Day | November 27 |
| Last Price | $52.61 |
| Previous Close | $52.60 |
| Change ($) | 0.01 |
| Change (%) | 0.02% |
| Day's Open | 51.58 |
| Day's Range | 51.44 - 52.77 |
| Day's Volume | 14,783,164 |
| 52-Week Range | 36.15 - 64.94 |
More Stats
| Market Cap | 138.08B |
| Enterprise Value | 151.97B |
| Earnings Date (est) | Feb 11, 2021 |
| Ex-Dividend Date | Aug 13, 2020 |
| Shares Outstanding | 2.62B |
| Float | 2.62B |
| EPS (basic) | 0.95 |
| EPS (diluted) | 0.95 |
| FCF / Share | 1.35 |
| Dividend | $1.40 |
| Dividend Yield | 2.66% |
| Earnings Yield | 1.81% |
| FCF Yield | 2.56% |
| Payout Ratio | 147.40% |
| Shares Short | 6.29M |
| Short Ratio | 1.38 |
| Short % of Float | 0.24% |
| Beta | 0.30 |
| PE Ratio | 55.38 |
| Forward PE | 22.83 |
| P/FCF Ratio | 39.11 |
| PS Ratio | 5.34 |
| PB Ratio | 11.90 |
| Revenue | 25.87B |
| Operating Income | 4.25B |
| Net Income | 2.42B |
| Free Cash Flow | 3.53B |
| Net Cash | -13.89B |
| Net Cash / Share | -5.29 |
| Gross Margin | 75.51% |
| Operating Margin | 16.44% |
| Profit Margin | 9.30% |
| FCF Margin | 13.65% |
| ROA | 5.22% |
| ROE | 17.71% |
| ROIC | 17.40% |
Analyst Forecasts
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24,384 | 22,090 | 22,465 | 23,002 | 24,708 | 26,547 | 25,806 | 27,973 | 33,591 | 33,269 |
| Revenue Growth | 10.38% | -1.67% | -2.33% | -6.9% | -6.93% | 2.87% | -7.75% | -16.72% | 0.97% | - |
| Gross Profit | 19,463 | 17,154 | 18,147 | 18,876 | 20,062 | 20,705 | 20,545 | 22,580 | 27,565 | 26,880 |
| Operating Income | 2,924 | 3,387 | 3,677 | 4,902 | 4,114 | 2,137 | 3,712 | 8,148 | 11,312 | 11,494 |
| Net Income | 1,227 | 2,050 | 2,868 | 3,406 | 2,826 | 1,235 | 2,571 | 6,270 | 9,950 | 8,081 |
| Shares Outstanding | 1,301 | 1,267 | 1,266 | 1,265 | 1,264 | 1,262 | 1,252 | 1,261 | 1,361 | 1,438 |
| Earnings Per Share | 0.52 | 0.85 | 1.19 | 1.38 | 1.12 | 0.49 | 1.02 | 2.47 | 3.63 | 2.79 |
| EPS Growth | -39.41% | -28.27% | -14.13% | 23.77% | 127.55% | -51.96% | -58.7% | -31.86% | 30.16% | - |
| Dividend Per Share | 1.40 | 1.40 | 1.40 | 1.40 | 2.35 | 2.80 | 2.80 | 2.85 | 2.70 | 2.41 |
| Dividend Growth | 0% | 0% | 0% | -40.43% | -16.07% | 0% | -1.75% | 5.56% | 12.03% | - |
| Operating Cash Flow | 4,861 | 3,831 | 4,730 | 5,234 | 5,174 | 8,792 | 8,719 | 9,536 | 12,368 | 13,854 |
| Capital Expenditures | -942 | -1,031 | -1,243 | -1,364 | -1,281 | -854 | -673 | -473 | -737 | -708 |
| Free Cash Flow | 3,919 | 2,800 | 3,487 | 3,870 | 3,893 | 7,938 | 8,046 | 9,063 | 11,631 | 13,146 |
| Cash & Equivalents | 6,218 | 5,680 | 4,554 | 5,902 | 6,853 | 7,155 | 10,013 | 8,524 | 11,819 | 12,550 |
| Total Debt | 18,227 | 19,113 | 17,807 | 16,808 | 15,053 | 10,843 | 10,376 | 10,310 | 9,328 | 9,222 |
| Net Cash / Debt | -12,009 | -13,433 | -13,253 | -10,906 | -8,200 | -3,688 | -363 | -1,786 | 2,491 | 3,328 |
| Assets | 61,377 | 60,651 | 63,354 | 62,526 | 60,056 | 58,595 | 55,899 | 53,534 | 52,830 | 56,127 |
| Liabilities | 46,781 | 46,607 | 46,712 | 45,857 | 41,547 | 38,949 | 32,646 | 29,588 | 29,364 | 32,717 |
| Book Value | 13,127 | 12,468 | 14,960 | 14,854 | 18,490 | 19,627 | 23,224 | 23,731 | 23,240 | 23,213 |
Company Profile
Company Details
| Full Name | AstraZeneca plc |
| Country | United Kingdom |
| Employees | 70,600 |
| CEO | Pascal Soriot |
Stock Information
| Ticker Symbol | AZN |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers—General |
| Unique Identifier | NASDAQ: AZN |
| IPO Date | May 12, 1993 |
Description
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); and Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.